For example, the treatment with cidomycin orally was found to promote small intestine transit rate and reduce serum levels of alanine aminotransferase (ALT), AST and TNF-α in NASH mouse model, indicating a potential of cidomycin in alleviating the severity of NASH by intestinal microbiota modulation [45]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.